Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Glatiramer acetate
Unknown
What it measured
Main measures
Computerized gait analysis: at the beginning of treatment and after 1 year
Walking and mobility
Who could take part
Relapsing MS · 18 and over
Inclusion Criteria: * Clinical diagnosis of multiple sclerosis * EDSS less than 5.5 * No cognitive disability Exclusion Criteria: * EDSS over 5.5 * Inability to cooperate with gait analysis
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.
Loading reviews and guidelines…
Related trials
- TWINS
Phase 3 · Not yet recruiting
Still running
- AIOLOS
Recruiting
Still running
- Full Responders
Phase 4 · Stopped early
Stopped early
- A Study to Learn More About The Safety of Diroximel Fumar…
Running, not recruiting
Still running
- A Open-label Study to Assess Response to COVID-19 Vaccine…
Phase 4 · Stopped early
Stopped: safety
- A Study to Asses Efficacy, Safety and Tolerability of Mon…
Phase 3 · Completed
Met its main goal
History
Started
May 2006
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error